NCT02724917View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

PHASE1/PHASE2SuspendedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

December 31, 2016

Conditions
Schizophrenia
Interventions
DRUG

APN1125

Oral solid dose form of APN1125

DRUG

Placebo

Placebo to match

Trial Locations (1)

90806

Collaborative Neuroscience Network, Long Beach

Sponsors

Lead Sponsor

CoMentis

Collaborators (1)

Alpharmagen, Inc.
All Listed Sponsors
collaborator

Alpharmagen, Inc.

INDUSTRY

lead

CoMentis

INDUSTRY